1610955-40-2

Upstream product

• 333361-23-2 1-[(4-benzyloxyphenyl)methyl]-5-bromo-2-methylbenzene 
• 1610955-26-4 (4-(benzyloxy)phenyl)(5-bromo-2-methylphenyl)methanol 
• 90050-59-2 5-bromo-2-methylbenzaldehyde 
• 6793-92-6 p-benzyloxyphenylbromide 
• 1610955-39-9 (2S,3S,4R,5S,6R)-2-(3-(4-(2-aminoethoxy)benzyl)-4-methylphenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1610955-41-3 C₃₃H₄₃NO₁₀S 
• 1610955-29-7 (2S,3S,4R,5S,6R)-2-(3-(4-hydroxybenzyl)-4-methylphenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1610955-27-5 (3-(4-(benzyloxy)benzyl)-4-methylphenyl)((3aS,5R,6S,6aS)-6-hydroxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methanone 

Relevant academic research and scientific papers

Discovery of LX2761, a sodium-dependent glucose cotransporter 1 (SGLT1) Inhibitor restricted to the intestinal lumen, for the treatment of diabetes

The increasing number of people afflicted with diabetes throughout the world is a major health issue. Inhibitors of the sodiumdependent glucose cotransporters (SGLT) have appeared as viable therapeutics to control blood glucose levels in diabetic patents. Herein we report the discovery of LX2761, a locally acting SGLT1 inhibitor that is highly potent in vitro and delays intestinal glucose absorption in vivo to improve glycemic control.

INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1

Inhibitors of sodium glucose cotransporter 1 (SGLT1), compositions comprising them, and methods of their use to treat diseases and disorders such as diabetes are disclosed. Particular compounds are of the formula (I): the various substituents of which are defined herein.